Search
BioVenture VoiCes Episode 10: Curie.Bio's Alexis Borisy
The Co-Founder and Operating Chairman of Curie.Bio, and serial entrepreneur, shares experiences from his early life, CombinatoRx,...
Jan 13
SF Healthcare Week: Verve's CEO on the company's two clinical programs, and more in the pipeline
Sek Kathiresan provides an update on the company's PCSK9 and ANGPTL3 clinical programs, as well for the preclinical LPA program.
Jan 12
Jon Norris shares highlights from the 2024 HSBC Venture Healthcare Full-Year Report
He provides a 2024 year-end recap and 2025 outlook DOWNLOAD THE FULL REPORT #Sponsored
Jan 10
Candid Therapeutics licensed a trispecific T-cell engager from WuXi Biologics today for autoimmune disease. Chairman & CEO Ken Song talks about T-cell engagers vs CAR-Ts for autoimmune
He describes two clinical programs that Candid currently has targeting BCMA and CD20. Plus, discovery programs with U.S. and China based...
Jan 6
Biotech CEO Sisterhood: A leadership series discussion on building an effective board, best practices for running meetings, hiring talent, and decision making
Sisterhood editorial board members Daphne Zohar (Seaport Therapeutics) and Luba Greenwood (Gallop Oncology) share their experiences about...
Jan 6
BioVenture VoiCes Episode 9: Alloy Therapeutics & 82VS's Errik Anderson
He describes his career path and learnings from the tech industry, co-founding Adimab, the work that Alloy and 82VS do to support and...
Dec 30, 2024
Biotech CEO Sisterhood: Heather Turner and Sheila Gujrathi discuss managing your board of directors effectively
Interviewed by Sisterhood editorial board member Sheila Gujrathi, former Carmot Therapeutics CEO and newly named CEO of LB Therapeutics...
Dec 19, 2024
PureTech Health's CEO and Co-Founder discuss this week's IPF data, the approval of Cobenfy in schizophrenia, and the company's unique hub and spoke business model
CEO Bharatt Chowrira and Co-Founder Eric Elenko describe the unmet need in IPF that exists today, and how their drug deupirfenidone was...
Dec 18, 2024
Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025
Jack Allen discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha...
Dec 18, 2024
Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC
He describes the rationale for PLK1 inhibition and highlights the significance of the data, which will have an additional update next...
Dec 16, 2024
Dimension's Zavain Dar talks about raising a $500M second fund, and describes the firm's ethos of investing in companies that are highly focused in both life sciences and technology
He discusses the founding of Dimension, and highlights entrepreneurs and portfolio companies that have matched the firm's focused...
Dec 16, 2024
Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more
He describes being first to market in the menin inhibitor space and the advantage he believes that gives Syndax, and he highlights other...
Dec 16, 2024
BioVenture VoiCes Episode 8: Canaan Partners' Julie Grant
A general partner the firm, she describes her career path, including time spent at Goldman Sachs and Genentech, before landing at Canaan...
Dec 16, 2024
Seattle based Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases
Co-founder and CEO Neil McDonnell describes the history of ASK1 and how Seal Rock's program has been optimized to avoid roadblocks that...
Dec 13, 2024
Seattle and San Carlos, CA based Nautilus Biotechnology is developing a platform that aims to revolutionize how researchers are able to see the proteome. CEO Sujal Patel tells us how it will work
He describes the shortcomings of high affinity assays and mass spectometry, and how the Nautilus system will be different. Plus, use...
Dec 12, 2024
Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program
CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and...
Dec 12, 2024
Biotech CEO Sisterhood: Melinta Therapeutics CEO Christine Miller on expanding the company into the acute care business, improving employee satisfaction, and her leadership principles
Interviewed by Sisterhood editorial board member Grace Colón, Christine Miller describes taking the job at Melinta after a business...
Dec 12, 2024
Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andrew Scharenberg describes the technical innovations they have come up with to help make it succeed
He describes Umoja's numerous platforms that are aimed at maximizing in vivo success, including the company's proprietary lentiviral...
Dec 11, 2024
At an Innovation Day event hosted by Illumina in La Jolla, CA, BiotechTV got a look at the new MiSeq i100 series of benchtop sequencers
Product manager Emmanuel Naouri walks us through the new instrument and its features, including consumables that can be stored at room...
Dec 11, 2024
ASH 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year
CMO Gianfranco Pittari describes the unmet neet in GvHD and how the donor derived microbiome treatment is designed to work. A patient has...
Dec 10, 2024
.png){kind=logo}
